452296-79-6 Usage
General Description
4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE is a chemical compound with the molecular formula C9H9NO2. It is a heterocyclic compound that contains a pyrrole ring and a pyridine ring fused together. 4,7-DIMETHOXY-1H-PYRROLO[2,3-C]PYRIDINE is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. Its structure and properties make it a valuable intermediate in organic synthesis, particularly in the development of new drugs and agricultural products. Additionally, it is used in research and development activities related to drug discovery and crop protection. Its chemical structure and functional groups make it a versatile precursor for various organic reactions, allowing for the creation of a wide range of analogs and derivatives with potentially valuable biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 452296-79-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,2,2,9 and 6 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 452296-79:
(8*4)+(7*5)+(6*2)+(5*2)+(4*9)+(3*6)+(2*7)+(1*9)=166
166 % 10 = 6
So 452296-79-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H10N2O2/c1-12-7-5-11-9(13-2)8-6(7)3-4-10-8/h3-5,10H,1-2H3
452296-79-6Relevant articles and documents
Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement
Tuyishime, Marina,Danish, Matt,Princiotto, Amy,Mankowski, Marie K.,Lawrence, Rae,Lombart, Henry-Georges,Esikov, Kirill,Berniac, Joel,Liang, Kuang,Ji, Jingjing,Ptak, Roger G.,Madani, Navid,Cocklin, Simon
, p. 5439 - 5445 (2015/01/08)
With the emergence of drug-resistant strains and the cumulative toxicities associated with current therapies, demand remains for new inhibitors of HIV-1 replication. The inhibition of HIV-1 entry is an attractive, yet underexploited therapeutic approach with implications for salvage and preexposure prophylactic regimens, as well as topical microbicides. Using the combination of a field-derived bioactive conformation template to perform virtual screening and iterative bioisosteric replacements, coupled with in silico predictions of absorption, distribution, metabolism, and excretion, we have identified new leads for HIV-1 entry inhibitors.
